Etid klinik pou Kansè san nan Maryland
29 etid pou Kansè san ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Oct 2, 2026 · NCT05724121Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06904066Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- MedStar Franklin Square Medical Center ( Site 0046), Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0056), Baltimore
- Maryland Oncology Hematology (MOH) ( Site 8000), Columbia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- ak 10 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 23, Baltimore
Ap rekriteFaz 3
Laj 18 a 71 · Tout sèks · Mizajou Sep 23, 2026 · NCT07504458Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 12 a 120 · Tout sèks · Mizajou Sep 22, 2026 · NCT05470491Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Sep 21, 2026 · NCT07162038Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 12 a 120 · Tout sèks · Mizajou Sep 18, 2026 · NCT05327023Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Christiana Care - Union Hospital, Elkton
- UM Saint Joseph Medical Center, Towson
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 17, 2026 · NCT04242095The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 12 a 120 · Tout sèks · Mizajou Sep 11, 2026 · NCT05436418Longitudinal Studies of Patient With FPDMM
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 100 Years · Tout sèks · Mizajou Sep 11, 2026 · NCT03854318A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- The Center for Cancer and Blood Disorders, Bethesda
Ap rekriteEtid obsèvasyon
Laj 0 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07154823Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
- John Hopkins University, Baltimore
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06184321Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
- Tania Jain, MD, Baltimore
Ap rekriteFaz 1
6 Months – 80 Years · Tout sèks · Mizajou Aug 14, 2026 · NCT02203903PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Johns Hopkins Hospital, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT06665100A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04068597Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 12 a 85 · Tout sèks · Mizajou Jun 11, 2026 · NCT04959175Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
- University of Maryland, Baltimore, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 5, 2026 · NCT06482515Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 1, 2026 · NCT05663502Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 120 · Tout sèks · Mizajou May 27, 2026 · NCT06856226A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Ap rekriteFaz 3
Laj 2 a 18 · Tout sèks · Mizajou May 5, 2026 · NCT05711667A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Johns Hopkins School of Medicine, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184Ocular Complications From Cancer Therapy - Patient Registry and Biobank
- Stoler Outpatient Cancer Center at the University of Maryland, Baltimore
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT06874283A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- University of Maryland Medical Center, Baltimore
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 25, 2025 · NCT05768269Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Johns Hopkins University, Baltimore
- National Cancer Institute, Pediatric Oncology Branch, Bethesda
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.